Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute

BUFFALO, NY--(Marketwired - Feb 9, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies elucidating immunotherapeutic...
February 02, 2016 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation

BUFFALO, NY--(Marketwired - Feb 2, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the...
January 26, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation

BUFFALO, NY--(Marketwired - Jan 26, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as...
January 21, 2016 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure

BUFFALO, NY--(Marketwired - Jan 21, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for...
December 22, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs and Rusnano Make Additional Investments in Panacela

BUFFALO, NY--(Marketwired - Dec 22, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO...
December 14, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute

BUFFALO, NY--(Marketwired - Dec 14, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI), Emory University and Roswell Park Cancer Institute (RPCI) today announced the publication of a study in...
November 30, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod

BUFFALO, NY--(Marketwired - Nov 30, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of two new patent applications by the U.S. Patent Office with claims that provide...
November 05, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress

BUFFALO, NY--(Marketwired - Nov 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter and nine-month period ended...
October 27, 2015 08:00 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5

BUFFALO, NY--(Marketwired - Oct 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2015, it will report its financial results for the third quarter and...
September 21, 2015 07:30 ET | Source: Cleveland BioLabs, Inc.

Department of Defense Grants Cleveland BioLabs Second Award for Advanced Development of Entolimod as a Medical Radiation Countermeasure

BUFFALO, NY--(Marketwired - Sep 21, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP)...